Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2004-10-29
2008-07-15
Kennedy, Sharon E. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
Reexamination Certificate
active
07399480
ABSTRACT:
A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to,This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal
patent: 3993749 (1976-11-01), Sehgal
patent: 4316885 (1982-02-01), Rakhit
patent: 4401653 (1983-08-01), Eng
patent: 4650803 (1987-03-01), Stella
patent: 4885171 (1989-12-01), Surendra
patent: 4916193 (1990-04-01), Tang
patent: 4994071 (1991-02-01), MacGregor
patent: 5023262 (1991-06-01), Caufield
patent: 5092877 (1992-03-01), Pinchuk
patent: 5120725 (1992-06-01), Kao
patent: 5120727 (1992-06-01), Kao
patent: 5120842 (1992-06-01), Failli
patent: 5163952 (1992-11-01), Froix
patent: 5177203 (1993-01-01), Failli
patent: 5288711 (1994-02-01), Mitchell et al.
patent: 5304121 (1994-04-01), Sahatjian
patent: 5447724 (1995-09-01), Helmus
patent: 5449382 (1995-09-01), Dayton
patent: 5457111 (1995-10-01), Luly
patent: 5464650 (1995-11-01), Berg
patent: 5516781 (1996-05-01), Morris et al.
patent: 5527337 (1996-06-01), Stack
patent: 5563146 (1996-10-01), Morris et al.
patent: 5605696 (1997-02-01), Eury
patent: 5609629 (1997-03-01), Fearnot et al.
patent: 5624411 (1997-04-01), Tuch
patent: 5646160 (1997-07-01), Morris et al.
patent: 5665728 (1997-09-01), Morris et al.
patent: 5705583 (1998-01-01), Bowers
patent: 5837313 (1998-11-01), Ding et al.
patent: 5869079 (1999-02-01), Wong et al.
patent: 6015815 (2000-01-01), Mollison
patent: 6033562 (2000-03-01), Budeit
patent: 6090901 (2000-07-01), Bowers
patent: 6096070 (2000-08-01), Ragheb et al.
patent: 6120536 (2000-09-01), Ding et al.
patent: 6273913 (2001-08-01), Wright
patent: 6284305 (2001-09-01), Ding
patent: 6299604 (2001-10-01), Ragheb
patent: 6358556 (2002-03-01), Ding
patent: 6413272 (2002-07-01), Igaki
patent: 6419692 (2002-07-01), Yang
patent: 6576259 (2003-06-01), Yamashita et al.
patent: 6585764 (2003-07-01), Wright et al.
patent: 6641611 (2003-11-01), Jayaraman
patent: 6726923 (2004-04-01), Iyer et al.
patent: 2003/0129215 (2003-07-01), Mollison
patent: 2003/0170287 (2003-09-01), Prescott
patent: 2005/0004661 (2005-01-01), Lewis
patent: 2005/0060028 (2005-03-01), Horres et al.
patent: 0184162 (1986-06-01), None
patent: 0467606 (1992-01-01), None
patent: 0 568 310 (1996-03-01), None
patent: 0747069 (2002-09-01), None
patent: 1 550 472 (2005-07-01), None
patent: 92/05179 (1992-04-01), None
patent: 98/36784 (1998-08-01), None
patent: 00/21584 (2000-04-01), None
patent: 01/87372 (2001-11-01), None
patent: WO 01/87375 (2001-11-01), None
patent: 02/055122 (2002-07-01), None
patent: 02094335 (2002-11-01), None
patent: 03/057218 (2003-07-01), None
patent: WO 2004/060283 (2004-07-01), None
patent: WO 2004/098495 (2004-11-01), None
patent: 2005/027972 (2005-03-01), None
patent: 2005/027973 (2005-03-01), None
Suzuki, et al., Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model, Circulation, pp. 1188-1193 (2001).
Aggarwal, A., D.J. Schneider, B.E. Sobel, and H.L. Dauerman. 2003. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol. 92:924-9.
Baker, H., A. Sidorowicz, S.N. Sehgal, and C. Vezina. 1978. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo). 31:539-45.
Bierer, B.E., S.L. Schreiber, and S.J. Burakoff. 1991. The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. Eur J Immunol. 21:439-45.
Biondi-Zoccai, G.G., A. Abbate, G. Liuzzo, and L.M. Biasucci. 2003. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol. 41:1071-7.
Brown, E.J., M.W. Albers, T.B. Shin, K. Ichikawa, C.T. Keith, W.S. Lane, and S.L. Schreiber. 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 369:756-8.
Bunchman, T.E., and C.A. Brookshire. 1991. Smooth muscle cell proliferation by conditioned media from cyclosporine-treated endothelial cells: a role of endothelin. Transplant Proc. 23:967-8.
Carter, A.J., M. Aggarwal, G.A. Kopia, F. Tio, P.S. Tsao, R. Kolata, A.C. Yeung, G. Llanos, J. Dooley, and R. Falotico. 2004. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 63:617-24.
Dandona, P., and A. Aljada. 2002. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol. 90:27G-33G.
Dumont, F.J., M.R. Melino, M.J. and Staruch, S.L. Koprak, P.A. Fischer, and N.H. Sigal. 1990. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol. 144:1418-24.
Fretz, H., M. Albers, A. Gala, R. Standaert, W. Lane, S. Burakoff, B. Bierer, and S. Schreiber. 1991. Rapamycin and FK506 binding proteins (immunophilins). J. Am. Chem. Soc. 113:1409-1411.
Grech, E.D., and D.R. Ramsdale. 2003. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. British Med. J. 326:1259-61.
Harding, M.W., A. Galat, D.E. Uehling, and S.L. Schreiber. 1989. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature. 341:758-60.
Hayward, C., D. Yohannes, and S. Danishefsky. 1993. Total synthesis of rapamycin via a novel titanium-mediated aldol macrocyclization reaction. J. Am. Chem. Soc. 115:9345-9346.
Helmus, M. 1990. Medical Device Design—A Systems Approach: Central Venous Catheters. In 22nd International Society for the Advancement of Material and Process Engineering Technical Conference.
Ji, Q., M. Reimer, and T. El-Shourbagy. 2004. 96-well liquid-liquid extraction liquid chromatography-tandem mass spectrometry method for the quantitative determination of ABT-578 in human blood samples. Journal of Chromatography B. 805:67-75.
Kino. T., N. Inamura, F. Sakai, K. Nakahara, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki, and T. Ochiai. 1987. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc. 19:36-9.
Kornowski, R., M.K. Hong, F.O. Tio, O. Bramwell, H. Wu, and M.B. Leon. 1998. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 31:224-30.
Martel, R.R., J. Klicius, and S. Galet. 1977. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol. 55:48-51.
Morris, R. 1992. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppresive macrolides. Transplant. Rev. 6:39-87.
Morris, R., and B. Meiser. 1989. Identification of a new pharmacologic action for an old compound. Med. Sci. Res. 17:609.
Nicolaou, K., T. Chakraborty, A. Piscopio, N. Minowa, and P. Bertinato. 1993. Total synthesis of rapamycin. J. Am. Chem. Soc. 115:4419-4420.
Paiva, N.L., A.L. Demain, and M.F. Roberts. 1991. Incorporation of acetate, propionate, and methionine into rapamycin byStreptomyces hygroscopicus. J Nat Proc. 54:167-77.
Roffi, M., and E.J. Topol. 2004. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 25:190-8.
Romo, D., S
Burke Sandra E.
Cromack Keith R.
LeCaptain Angela M.
Mollison Karl W.
Tarcha Peter J.
Abbott Laboratories
Kennedy Sharon E.
Squire Sanders & Dempsey L.L.P.
LandOfFree
Methods of administering tetrazole-containing rapamycin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of administering tetrazole-containing rapamycin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of administering tetrazole-containing rapamycin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3964764